Synlogic 将来の成長

Future 基準チェック /06

Synlogicの収益は年間118.4%で減少すると予測されていますが、年間利益は年間82.9%で増加すると予想されています。EPS は年間83.5%で増加すると予想されています。

主要情報

82.9%

収益成長率

83.5%

EPS成長率

Biotechs 収益成長	37.0%
収益成長率	-118.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	16 Aug 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

LSE:0A8U - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-3	N/A	N/A	1
12/31/2025	N/A	-6	N/A	N/A	1
12/31/2024	N/A	-33	N/A	N/A	1
9/30/2024	3	-37	-37	-37	N/A
6/30/2024	3	-49	-49	-49	N/A
3/31/2024	3	-73	-46	-46	N/A
12/31/2023	3	-57	-52	-52	N/A
9/30/2023	1	-59	-59	-58	N/A
6/30/2023	1	-65	-61	-61	N/A
3/31/2023	1	-66	-63	-63	N/A
12/31/2022	1	-66	-58	-57	N/A
9/30/2022	2	-65	-58	-58	N/A
6/30/2022	2	-63	-57	-56	N/A
3/31/2022	2	-61	-55	-54	N/A
12/31/2021	2	-61	-53	-52	N/A
9/30/2021	1	-60	-50	-49	N/A
6/30/2021	0	-57	-44	-43	N/A
3/31/2021	0	-58	-41	-41	N/A
12/31/2020	1	-59	-40	-40	N/A
9/30/2020	2	-57	-42	-41	N/A
6/30/2020	2	-57	-44	-43	N/A
3/31/2020	2	-54	-76	-75	N/A
12/31/2019	2	-51	-77	-75	N/A
9/30/2019	1	-51	-75	-73	N/A
6/30/2019	3	-48	-76	-72	N/A
3/31/2019	3	-50	-47	-43	N/A
12/31/2018	3	-48	-48	-42	N/A
9/30/2018	3	-48	-47	-43	N/A
6/30/2018	1	-49	N/A	-40	N/A
3/31/2018	3	-44	N/A	-37	N/A
12/31/2017	2	-40	N/A	-31	N/A
9/30/2017	2	-36	N/A	-29	N/A
6/30/2017	2	-29	N/A	-26	N/A
3/31/2017	0	-24	N/A	-23	N/A
12/31/2016	0	-21	N/A	-20	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 0A8U今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 0A8U今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 0A8U今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 0A8U来年は収益がないと予測されています。

高い収益成長: 0A8U来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 0A8Uの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Synlogic 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Third quarter 2024 earnings released: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023)

Synlogic, Inc., Annual General Meeting, Dec 04, 2024

New major risk - Share price stability

New major risk - Financial position

Second quarter 2024 earnings released: EPS: US$0.17 (vs US$3.21 loss in 2Q 2023)

New major risk - Financial position

First quarter 2024 earnings released: US$2.60 loss per share (vs US$3.39 loss in 1Q 2023)

Cable Car Capital Discloses its Views on Synlogic

Synlogic, Inc. Announces Departure of Aoife Brennan as Chief Executive Officer

Synlogic, Inc. Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023

Third quarter 2023 earnings released: US$2.57 loss per share (vs US$3.73 loss in 3Q 2022)

Synlogic, Inc. Announces Implementation of Reduction in Workforce

Synlogic, Inc. Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Synlogic, Inc. Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria

Synlogic, Inc. Appoints Dave Hava as Head of Research and Development

Synlogic Receives Non-Compliance Notice From Nasdaq

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU) SYNB1934 Advances to Phase 3

Synlogic, Inc Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Synlogic, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Synlogic, Inc. Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria

Synlogic, Inc. Announces Appointment of Brendan St. Amant as Corporate Secretary, Effective July 1, 2022

Synlogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs At the Society for Inherited Metabolic Disorders 43Rd Annual Meeting

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

High number of new directors

Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting

High number of new directors

Synlogic Announces Initiation of Phase 1 Study of SYNB1934 for treatment of Phenylketonuria

Synlogic, Inc. Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Independent Director Chau Khuong has left the company

Synlogic, Inc. Provides Update on its Clinical and Preclinical Programs

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘